Renal, hematologic and infectious complications in multiple myeloma.

[1]  P. Verroust,et al.  Renal lesions in dysproteinemias , 2005, Springer Seminars in Immunopathology.

[2]  Bart Barlogie,et al.  Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation , 2004, British journal of haematology.

[3]  L. Villela,et al.  Aminoglycoside-associated Severe Renal Failure in Patients with Multiple Myeloma Treated with Thalidomide , 2004, Leukemia & lymphoma.

[4]  R. Fonseca,et al.  Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. , 2004, Blood.

[5]  J. Bladé,et al.  Management of myeloma patients with renal failure , 2004 .

[6]  G. Gahrton,et al.  Multiple Myeloma and Related Disorders , 2004 .

[7]  B. Barlogie,et al.  Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant , 2004, Bone Marrow Transplantation.

[8]  M. Dimopoulos,et al.  Treatment of plasma cell dyscrasias with thalidomide and its derivatives. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[10]  Terry M Therneau,et al.  Review of 1027 patients with newly diagnosed multiple myeloma. , 2003, Mayo Clinic proceedings.

[11]  V. Rossi,et al.  Risk factors for the development of bacterial infections in patients with multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules , 2003 .

[12]  S. Woolf,et al.  Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Gertz,et al.  Autologous stem cell transplantation for primary systemic amyloidosis. , 2002, Blood.

[14]  F. Dammacco,et al.  Anemia in Multiple Myeloma: Role of Deregulated Plasma Cell Apoptosis , 2002, Leukemia & lymphoma.

[15]  J. San Miguel,et al.  Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations. , 2002, The hematology journal : the official journal of the European Haematology Association.

[16]  B. Barlogie,et al.  Results of autologous stem cell transplant in multiple myeloma patients with renal failure , 2001, British journal of haematology.

[17]  M. Skinner,et al.  Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. , 2001, Blood.

[18]  J. Esteve,et al.  Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients. , 2001, The hematology journal : the official journal of the European Haematology Association.

[19]  L. Knudsen,et al.  Renal failure in multiple myeloma: reversibility and impact on the prognosis , 2000, European journal of haematology.

[20]  C. Solano,et al.  Are myeloma patients with renal failure candidates for autologous stem cell transplantation? , 2000, The hematology journal : the official journal of the European Haematology Association.

[21]  C. Bueso-Ramos,et al.  Primary myeloid leukemia presenting concomitantly with primary multiple myeloma: two cases and an update of the literature. , 1999, Leukemia & lymphoma.

[22]  S. Montoto,et al.  Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. , 1998, Archives of internal medicine.

[23]  M. Dhodapkar,et al.  Biology and therapy of immunoglobulin deposition diseases. , 1997, Hematology/oncology clinics of North America.

[24]  B. Barlogie,et al.  Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma , 1996, British journal of haematology.

[25]  M. Oken,et al.  Prophylactic antibiotics for the prevention of early infection in multiple myeloma. , 1996, The American journal of medicine.

[26]  E. Montserrat,et al.  Patients with multiple myeloma requiring long‐term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases , 1995, British journal of haematology.

[27]  H. Chapel,et al.  Immunological factors and risk of infection in plateau phase myeloma. , 1995, Journal of clinical pathology.

[28]  B. Hoen,et al.  Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicentre prospective survey. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[29]  R. Kyle,et al.  Myeloma : biology and management , 1995 .

[30]  R. Kyle,et al.  Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  F. Boege,et al.  Structural features related to the nephropathogenicity of Bence-Jones proteins. , 1994, Kidney international. Supplement.

[32]  E. Holmberg,et al.  Renal function in newly diagnosed multiple myeloma — A demographic study of 1353 patients , 1994, European journal of haematology.

[33]  A. Khamlichi,et al.  Monoclonal immunoglobulin deposition disease (Randall type). Relationship with structural abnormalities of immunoglobulin chains. , 1994, Kidney international.

[34]  P. Sanders,et al.  Pathogenesis and treatment of myeloma kidney. , 1994, The Journal of laboratory and clinical medicine.

[35]  L. Snowdon,et al.  Frequency of infection in plateau-phase multiple myeloma , 1994, The Lancet.

[36]  G. Fillet,et al.  Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production , 1992, British journal of haematology.

[37]  S. Krantz,et al.  Progress in understanding the pathogenesis of the anemia of chronic disease. , 1992, Blood.

[38]  M. Goldberg,et al.  EFFECT OF INFLAMMATORY CYTOKINES ON HYPOXIA-INDUCED ERYTHROPOIETIN PRODUCTION , 1992 .

[39]  P. Zucchelli,et al.  Long-term survival patients with acute and severe renal failure due to multiple myeloma. , 1990, Clinical nephrology.

[40]  J. Feehally,et al.  The role of continuous ambulatory peritoneal dialysis in end-stage renal failure due to multiple myeloma. , 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[41]  B. Barlogie,et al.  Renal Failure in Multiple Myeloma , 1990 .

[42]  B. Barlogie,et al.  Renal failure in multiple myeloma. Pathogenesis and prognostic implications. , 1990, Archives of internal medicine.

[43]  H. Gisslinger,et al.  Erythropoietin treatment of anemia associated with multiple myeloma. , 1990, The New England journal of medicine.

[44]  I. Reilly,et al.  Vincristine, adriamycin and high dose steroids in myeloma complicated by renal failure. , 1990, British Journal of Cancer.

[45]  W. J. Johnson,et al.  Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. , 1990, Archives of internal medicine.

[46]  E. Werner,et al.  Correlation between neopterin, interferon‐gamma and haemoglobin in patients with haematological disorders , 1990, European journal of haematology.

[47]  G. Mufti,et al.  Chronic dialysis in patients with multiple myeloma and renal failure: a worthwhile treatment. , 1989, The Quarterly journal of medicine.

[48]  D. Bergsagel.  Chemotherapy of myeloma: Drug combinations versus single agents, an overview, and comments on acute leukemia in myeloma , 1988, Hematological oncology.

[49]  A. Lupo,et al.  Prognostic factors and effectiveness of treatment in acute renal failure due to multiple myeloma: a review of 50 cases. Report of the Italien Renal Immunopathology Group. , 1987, Clinical nephrology.

[50]  G. Mecca,et al.  Management of myeloma kidney: an anti-light-chain approach. , 1987, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[51]  J. Cuzick,et al.  A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults. , 1987, British Journal of Cancer.

[52]  P. Verroust,et al.  Multiple Myeloma and Severe Renal Failure: A Clinicopathologic Study of Outcome and Prognosis in 34 Patients , 1987, Medicine.

[53]  L. M. Cobb,et al.  The diffusion of a tumour-specific monoclonal antibody in lymphoma infiltrated spleen. , 1987, British Journal of Cancer.

[54]  E. Kansu,et al.  Serum bactericidal and opsonic activities in chronic lymphocytic leukemia and multiple myeloma , 1986, American journal of hematology.

[55]  S. Zolla-Pazner,et al.  Immunosuppression and infection in multiple myeloma. , 1986, Seminars in oncology.

[56]  M. Gobbi,et al.  Renal failure in multiple myeloma. A study of the presenting findings, response to treatment and prognosis in 26 patients. , 1986, Nouvelle revue francaise d'hematologie.

[57]  R. Matre,et al.  Mechanisms of decreased leucocyte adhesiveness and migration in plasma from patients with IgG myelomatosis. , 2009, Scandinavian journal of haematology.

[58]  P. Verroust,et al.  Renal failure in myeloma: relationship with isoelectric point of immunoglobulin light chains. , 1984, Clinical nephrology.

[59]  B. Barlogie,et al.  Effective treatment of advanced multiple myeloma refractory to alkylating agents. , 1984, The New England journal of medicine.

[60]  F. Rosner,et al.  Simultaneous occurrence of multiple myeloma and acute myeloblastic leukemia: fact or myth? , 1984, The American journal of medicine.

[61]  E. L. Robinson,et al.  The importance of urinary immunoglobulin light chain isoelectric point (pI) in nephrotoxicity in multiple myeloma. , 1984, Clinical science.

[62]  G. Appel,et al.  Acute renal failure in patients with multiple myeloma. , 1984, The American journal of medicine.

[63]  H. Birgens,et al.  Antibody response to pneumococcal vaccination in patients with myelomatosis. , 2009, Scandinavian journal of haematology.

[64]  J. Cawley,et al.  Abnormal monoclonal antibody‐defined helper/suppressor T‐cell subpopulations in multiple myeloma: relationship to treatment and clinical stage , 1983, British journal of haematology.

[65]  G. Hill,et al.  Renal lesions in multiple myeloma: their relationship to associated protein abnormalities. , 1983, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[66]  H. Humes,et al.  Reversible renal insufficiency in multiple myeloma. , 1982, Archives of internal medicine.

[67]  P. Appelbaum,et al.  Changing patterns of infections in patients with multiple myeloma. , 1982, Oncology.

[68]  R. Kyle,et al.  "Idiopathic" Bence Jones proteinuria: long-term follow-up in seven patients. , 1982, The New England journal of medicine.

[69]  Bergsagel De.  Plasma cell neoplasms and acute leukaemia. , 1982 .

[70]  D. Savage,et al.  Biphasic pattern of bacterial infection in multiple myeloma. , 1982, Annals of internal medicine.

[71]  M. Oken,et al.  Influence of treatment and response status on infection risk in multiple myeloma. , 1981, The American journal of medicine.

[72]  G. Schiffman,et al.  Polyvalent pneumococcal immunization of patients with plasma cell dyscrasias , 1981, Cancer.

[73]  G. Schmid,et al.  Antibody response to pneumococcal vaccine in patients with multiple myeloma. , 1981, The Journal of infectious diseases.

[74]  M. Lederman,et al.  Pneumococcal vaccination: the response of patients with multiple myeloma. , 1980, The American journal of medicine.

[75]  B. Cheson,et al.  Defective opsonization in multiple myeloma. , 1980, Blood.

[76]  Johnson Wj,et al.  Dialysis in the treatment of multiple myeloma. , 1980 .

[77]  A. Miller,et al.  The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. , 1979, The New England journal of medicine.

[78]  R. Macgregor,et al.  Impaired granulocyte adherence in multiple myeloma: relationship to complement system, granulocyte delivery, and infection. , 1978, Blood.

[79]  M. Y. Tung,et al.  Manifestations of systemic light chain deposition. , 1976, The American journal of medicine.

[80]  T. Waldmann,et al.  Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma Role of suppressor cells. , 1975, The New England journal of medicine.

[81]  R. DeFronzo,et al.  ACUTE RENAL FAILURE IN MULTIPLE MYELOMA , 1975, Medicine.

[82]  R. Kyle.  Multiple myeloma: review of 869 cases. , 1975, Mayo Clinic proceedings.

[83]  B. Meyers,et al.  Current patterns of infection in multiple myeloma. , 1972, The American journal of medicine.

[84]  J. Fahey,et al.  INFECTION, ANTIBODY RESPONSE AND GAMMA GLOBULIN COMPONENTS IN MULTIPLE MYELOMA AND MACROGLOBULINEMIA. , 1963, The American journal of medicine.

[85]  W. H. Hall,et al.  A review of fifty-one cases of multiple myeloma; emphasis on pneumonia and other infections as complications. , 1959, A.M.A. archives of internal medicine.

[86]  W. H. Hall,et al.  Recurrent pneumonia in multiple myeloma and some observations on immunologic response. , 1954, Annals of internal medicine.